News

(RTTNews) - Legend Biotech Corporation (LEGN), a biopharmaceutical company specializing in innovative cell therapies, has announced positive results from its CARTITUDE-4 trial.

CARTITUDE-4 is a phase III trial that evaluated the efficacy and safety of CARVYKT (ciltacabtagene autocel) in adult patients who received one to three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMiD).

The trial demonstrated that CARVYKTI significantly improves overall survival in patients with relapsed and lenalidomide-refractory multiple myeloma.

Multiple myeloma is a type of cancer that affects plasma cells, which accumulate in the bone marrow and produce abnormal proteins.

Compared to standard treatments, CARVYKTI demonstrated a meaningful survival benefit with a one-time infusion.

These findings, align with CARVYKTI's established safety profile and no new safety concerns, were identified.

The results will be presented at a medical meeting and discussed with regulatory agencies for potential label updates.

Carvykti received FDA approval in April of this year for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide. The drug was approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and anti-CD38 monoclonal antibody in February 2022.

In the first quarter of 2024, CARVYKT generated $157 million in sales, compared to $72 million in the same period of 2023.

LEGN has traded in a range of $38.60 to $77.32 in the last 1 year. As of pre-market, the stock is at $45.83, down 0.41%

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.